Global Psychedelic Therapeutics Market by Roots Analysis

Psychedelic substances have been demonstrated to interact with a variety of neurotransmitter pathways, including those involving serotonin, acetylcholine, norepinephrine, and dopamine. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of psychedelic substances. Further, experts believe that psychedelics, at appropriate doses, can be used to address some of the serious psychological implications associated with the COVID-19 pandemic.

To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this –

The over USD 6.5 billion (by 2030) financial opportunity within the psychedelic therapeutics market has been analyzed across the following segments:
 Target Disease Indication
 Anxiety and Depression
 Trauma
 Pain Disorder
 Sleep related Disorder

 Origin of Psychedelic Substance
 Natural
 Synthetic

 Type of Psychedelic Substance
 Gamma-hydroxybutyrate
 Ketamine
 Psilocybin

 Route of Administration
 Oral
 Intranasal
 Sublingual

 Key Geographies
 North America
 Europe
 Asia-Pacific

The Global Psychedelic Therapeutics Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
 Celon Pharma
 iX Biopharma
 MAPS Public Benefit
 MindMed
 Janssen Pharmaceuticals
 Jazz Pharmaceutical

To request for sample –
Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape: Psychedelic Therapeutics

5. Company Profiles

6. Clinical Trial Analysis

7. Clinical Trial Site Analysis

9. Key Opinion Leader (KOL) Analysis

8. Academic Grants Analysis

10. Partnerships and Collaborations

11. Mergers and Acquisitions

12. Market Forecast and Opportunity Analysis

Leave a Reply

Your email address will not be published. Required fields are marked *